We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+15.53%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$254M
AUM Growth
-$32.6M
Cap. Flow
-$20.3M
Cap. Flow %
-8%
Top 10 Hldgs %
68.51%
Holding
44
New
8
Increased
7
Reduced
10
Closed
12
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.6 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$9.69M
2
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$8.8M
3
NTLA icon
Intellia Therapeutics
NTLA
+$8.27M
4
DERM icon
Dermira, Inc.
DERM
+$7.51M
5
AKAO
Achaogen Inc
AKAO
+$5.47M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$20.3M
2
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$10.5M
3
EPZM
Epizyme, Inc
EPZM
+$9.41M
4
AIMT
Aimmune Therapeutics
AIMT
+$7.07M
5
KITE
Kite Pharma, Inc.
KITE
+$6.89M

Sector Composition

Rank Sector Weight
1 Healthcare 86.15%
2 Miscellaneous 13.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$595M
$31.8M 12.53%
2,901,958
+440,626
+18% +$4.31M
2015 Q4
2 quarters
LKFT icon
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
$24.4M 9.61%
439,385
+192,694
+78% +$9.69M
2015 Q4
2 quarters
TVTX icon
3
Travere Therapeutics
TVTX
$5.02B
$21.8M 8.6%
1,225,084
– –
2015 Q1
5 quarters
CYTK icon
4
Cytokinetics
CYTK
$8.82B
$20.3M 8.01%
2,139,697
+86,897
+4% +$713K
2015 Q4
2 quarters
ASMB icon
5
Assembly Biosciences
ASMB
$418M
$16.3M 6.44%
245,264
+70,405
+40% +$4.62M
2014 Q4
6 quarters
KYNB icon
6
Kyntra Bio
KYNB
$22.6M
$12.9M 5.1%
31,550
-3,000
-9% -$1.37M
2014 Q4
6 quarters
XLRN
7
DELISTED
Acceleron Pharma
XLRN
$12.6M 4.98%
371,381
+101,092
+37% +$3.29M
2016 Q1
1 quarter
GILD icon
8
CALL
Gilead Sciences
GILD
$190B
$12.5M 4.93%
150,000
– –
2015 Q3
3 quarters
AGN
9
CALL
DELISTED
Allergan plc
AGN
$11.6M 4.56%
+50,000
New +$11.5M
2016 Q2
0 quarters
ITCI icon
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.51M 3.75%
+244,950
New +$8.8M
2016 Q2
0 quarters
DERM icon
11
DELISTED
Dermira, Inc.
DERM
$7.96M 3.14%
+272,000
New +$7.51M
2016 Q2
0 quarters
EPZM
12
DELISTED
Epizyme, Inc
EPZM
$7.73M 3.05%
755,046
-843,854
-53% -$9.41M
2015 Q1
5 quarters
IRWD icon
13
CALL
Ironwood Pharmaceuticals
IRWD
$595M
$7.61M 3%
694,311
+336,111
+94% +$3.28M
2016 Q1
1 quarter
KURA icon
14
Kura Oncology
KURA
$855M
$6.68M 2.63%
2,465,286
– –
2015 Q4
2 quarters
NTLA icon
15
Intellia Therapeutics
NTLA
$1.6B
$6.63M 2.62%
+310,695
New +$8.27M
2016 Q2
0 quarters
AKAO
16
DELISTED
Achaogen Inc
AKAO
$5.96M 2.35%
+1,571,708
New +$5.47M
2016 Q2
0 quarters
ONC icon
17
BeOne Medicines Ltd
ONC
$39.8B
$5.23M 2.06%
175,380
+159,614
+1,012% +$4.68M
2016 Q1
1 quarter
KIN
18
DELISTED
Kindred Biosciences, Inc.
KIN
$5.07M 2%
1,432,765
– –
2014 Q4
6 quarters
NBRV
19
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$4.22M 1.66%
2,251
-580
-20% -$1.17M
2015 Q3
3 quarters
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.21B
$3.52M 1.39%
357,365
-153,464
-30% -$2.1M
2016 Q1
1 quarter
COLL icon
21
Collegium Pharmaceutical
COLL
$733M
$3.34M 1.32%
281,776
-191,347
-40% -$3.16M
2015 Q2
4 quarters
XNCR icon
22
Xencor
XNCR
$1.74B
$3.19M 1.26%
+168,000
New +$2.3M
2016 Q2
0 quarters
ENTA icon
23
Enanta Pharmaceuticals
ENTA
$326M
$3.02M 1.19%
136,882
-103,501
-43% -$2.71M
2016 Q1
1 quarter
EDIT icon
24
Editas Medicine
EDIT
$349M
$2.08M 0.82%
85,469
-2,452
-3% -$82.7K
2016 Q1
1 quarter
ARRY icon
25
CALL
DELISTED
Array Biopharma Inc
ARRY
$1.85M 0.73%
520,000
– –
2016 Q1
1 quarter
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2016 Portfolio in Review

As of Q2 2016, EcoR1 Capital held 44 positions worth $254M, down 11% from $286M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

EcoR1 Capital withdrew a net $20.3M in Q2 2016, closing 12 positions and reducing 10 holdings. Its most notable exit was Five Prime Therapeutics, Inc., an estimated $20.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 76% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Intra-Cellular Therapies Inc. worth $9.51M.

  • EcoR1 Capital's largest Q2 2016 buy was Intra-Cellular Therapies Inc.: 244,950 shares worth $9.51M.
  • EcoR1 Capital added most to Lakefront Biotherapeutics American Depositary Shares in Q2 2016, an estimated $9.69M increase.
  • EcoR1 Capital's biggest Q2 2016 reduction was Epizyme, Inc, cutting an estimated $9.41M.
  • EcoR1 Capital fully exited Five Prime Therapeutics, Inc. in Q2 2016, selling an estimated $20.3M.
  • EcoR1 Capital's ten largest holdings make up 69% of its $254M portfolio in Q2 2016.
  • EcoR1 Capital opened 8 new positions and closed 12 in Q2 2016.
  • EcoR1 Capital's portfolio value fell 11% quarter-over-quarter to $254M.

Based on EcoR1 Capital's 13F filing for Q2 2016, filed 15 Aug 2016.